Pfizer (PFE) Income from Non-Controlling Interests (2009 - 2026)

Pfizer (PFE) has 18 years of Income from Non-Controlling Interests data on file, last reported at $8.0 million in Q1 2026.

• Quarterly Income from Non-Controlling Interests rose 33.33% year-over-year to $8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.0 million (up 48.28% YoY) and the FY2025 annual result came in at $41.0 million, up 32.26% from the prior year.
• Income from Non-Controlling Interests held at $8.0 million in Q1 2026 per PFE's latest filing, from $8.0 million in the prior quarter.
• Across five years, Income from Non-Controlling Interests topped out at $18.0 million in Q2 2025 and bottomed at $6.0 million in Q2 2022.
• The 5-year median for Income from Non-Controlling Interests is $8.0 million (2024), against an average of $9.2 million.
• The widest annual swing landed in 2022, when Income from Non-Controlling Interests tumbled 76.92%; it then surged 157.14% in 2025.
• Tracing PFE's Income from Non-Controlling Interests over 5 years: stood at $15.0 million in 2022, then slumped by 40.0% to $9.0 million in 2023, then dropped by 11.11% to $8.0 million in 2024, then changed by 0.0% to $8.0 million in 2025, then changed by 0.0% to $8.0 million in 2026.
• Per Business Quant, the three latest PFE Income from Non-Controlling Interests figures stand at $8.0 million (Q1 2026), $8.0 million (Q4 2025), and $9.0 million (Q3 2025).

Peer Comparison